Skip to main content
Onconetix, Inc. logo

Onconetix, Inc. — Investor Relations & Filings

Ticker · ONCO ISIN · US68237Q1040 US Manufacturing
Open in API
Filings indexed 343 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country US United States of America
Listing US ONCO

About Onconetix, Inc.

https://www.onconetix.com/

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of proprietary solutions. The company develops therapeutics, diagnostics, and services primarily for men's health and oncology.

Recent filings

Filing Released Lang Actions
REGISTRATION STATEMENT
Regulatory Filings Classification · 87% confidence The document is a Form S-1 Registration Statement filed under the Securities Act of 1933, detailing the offering and sale of shares (an equity line of credit financing) by Onconetix, Inc. It is not an annual report (10-K), interim report (IR), earnings release (ER), or any of the specific transaction categories like M&A or share repurchase. It is a regulatory compliance filing registering securities for sale. Under the defined categories, this best fits “Regulatory Filings” (RNS), which serves as the fallback for miscellaneous SEC filings including registration statements that do not fit other report types.
2026-06-08 English
CURRENT REPORT
Share Issue/Capital Change Classification · 85% confidence The document is a Current Report on Form 8-K disclosing Item 5.03—the approval and implementation of a 1-for-10 reverse stock split (a change in the company’s capital structure through a stock split). It does not contain full financial statements or earnings data, nor is it merely a publication announcement. It is a notification of a capital change (reverse stock split). Under the classification definitions, announcements of stock splits and other capital changes fall under Share Issue/Capital Change (SHA).
2026-05-19 English
CURRENT REPORT
Regulatory Filings Classification · 90% confidence The document is a U.S. SEC Form 8-K “Current Report” under Section 13 or 15(d) of the Exchange Act, with Items 8.01 (Other Events) and 9.01 (Exhibits) describing a press release being furnished as Exhibit 99.1. It does not contain actual financial statements or detailed periodic results but is a regulatory filing of an 8-K. This fits the catch‐all category for miscellaneous regulatory announcements.
2026-05-13 English
10-Q - Onconetix, Inc. (0001782107) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
S-1/A - Onconetix, Inc. (0001782107) (Filer)
Regulatory Filings Classification · 90% confidence The document is an SEC “Amendment No. 1 to Form S-1” registration statement for Onconetix, Inc., filed under the Securities Act of 1933. It is a compliance filing containing exhibits and amendments to the original Form S-1 rather than a financial report, proxy statement, or presentation. It does not include substantive financial statements or management discussion but is a regulatory submission. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-07 English
8-K - Onconetix, Inc. (0001782107) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 24, 2026, reporting changes in the company's board of directors and officers. It details the resignation of two directors and the election of a new chairman and a new board member, including their roles and compensation. There is no financial data or earnings information presented. The primary content is about management and board changes, which fits the category of Board/Management Information (MANG). The document length is 8193 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the appropriate classification is MANG with high confidence.
2026-04-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.